Nitroxoline Enhances Radiosensitivity in Non-Small Cell Lung Cancer by Suppressing STAT3-AKT-MTOR Survival Signaling - PubMed
6 hours ago
- #NSCLC
- #Radiosensitivity
- #Nitroxoline
- Nitroxoline enhances radiosensitivity in non-small cell lung cancer (NSCLC) by suppressing STAT3-AKT-mTOR survival signaling.
- Radiotherapy is a central treatment for NSCLC, but its effectiveness is often limited by radioresistance due to prosurvival signaling pathways.
- Nitroxoline, an antimicrobial agent with STAT3-inhibitory activity, was found to significantly enhance radiation-induced cytotoxicity and suppress clonogenic survival in NSCLC cells.
- The study showed that nitroxoline suppresses both basal and radiation-induced activation of STAT3, AKT, and mTOR pathways.
- Combination treatment of nitroxoline and radiation increased apoptosis, evidenced by elevated p53 expression and enhanced PARP and caspase-3 cleavage.
- Nitroxoline also amplified radiation-induced DNA damage signaling, leading to increased γ-H2AX and DNA-PKcs accumulation.
- The findings suggest repurposing nitroxoline as a radiosensitizer to improve radiotherapy outcomes in NSCLC patients.